598 / 1498
Can cytotoxic chemotherapy be avoided
?
The "RELEVANCE" Trial (Rituximab and Lenalidomide Versus Any
Chemotherapy)
• Phase 3 randomized Study to Compare the Efficacy and Safety of
Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus
Chemotherapy Followed by Rituximab in Untreated Follicular Lymphoma.
• Comparator R-CHOP, R-CVP, R-Bendamustine.
• 7 to 8 weeks later responding patients will continue with 375 mg/m2
rituximab every 8 weeks for 12 cycles.